thymalfasin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== Poisoning == The prognosis is good for paracetamol overdoses if treatment is initiated up to 8 hours after the drug has been taken. Most hospitals stock the antidote (acetylcysteine), which replenishes the liver's supply of glutathione, allowing the NAPQI to be metabolized safely. Without early administration of the antidote, fulminant liver failure follows, often in combination with kidney failure, and death generally occurs within several days.
==== MeSH E05.200.500 – cytological techniques ==== MeSH E05.200.500.105 – autoradiography MeSH E05.200.500.195 – cell count MeSH E05.200.500.195.107 – blood cell count MeSH E05.200.500.195.107.330 – erythrocyte count MeSH E05.200.500.195.107.330.725 – reticulocyte count MeSH E05.200.500.195.107.595 – leukocyte count MeSH E05.200.500.195.107.595.500 – lymphocyte count MeSH E05.200.500.195.107.595.500.150 – cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 – cd4-cd8 ratio MeSH E05.200.500.195.107.740 – platelet count MeSH E05.200.500.195.870 – sperm count MeSH E05.200.500.251 – cell fractionation MeSH E05.200.500.307 – cell fusion MeSH E05.200.500.363 – cell separation MeSH E05.200.500.363.285 – cytapheresis MeSH E05.200.500.363.285.570 – leukapheresis MeSH E05.200.500.363.285.790 – plateletpheresis MeSH E05.200.500.363.400 – immunomagnetic separation MeSH E05.200.500.363.540 – leukocyte reduction procedures MeSH E05.200.500.383 – colony-forming units assay MeSH E05.200.500.383.910 – tumor stem cell assay MeSH E05.200.500.385 – cytogenetic analysis MeSH E05.200.500.385.130 – chromosome banding MeSH E05.200.500.385.500 – mitotic index MeSH E05.200.500.386 – cytophotometry MeSH E05.200.500.386.350 – flow cytometry MeSH E05.200.500.386.400 – image cytometry MeSH E05.200.500.386.400.500 – laser scanning cytometry MeSH E05.200.500.387 – diffusion chambers, culture MeSH E05.200.500.388 – drug screening assays, antitumor MeSH E05.200.500.388.930 – tumor stem cell assay MeSH E05.200.500.410 – electroporation MeSH E05.200.500.607 – histocytochemistry MeSH E05.200.500.607.512 – immunohistochemistry MeSH E05.200.500.607.790 – periodic acid-schiff reaction MeSH E05.200.500.607.810 – prussian blue reaction MeSH E05.200.500.620 – histocytological preparation techniques MeSH E05.200.500.620.530 – microtomy MeSH E05.200.500.620.530.160 – cryoultramicrotomy MeSH E05.200.500.620.530.160.260 – frozen sections MeSH E05.200.500.620.620 – replica techniques MeSH E05.200.500.620.620.150 – corrosion casting MeSH E05.200.500.620.620.260 – freeze fracturing MeSH E05.200.500.620.620.260.400 – freeze etching MeSH E05.200.500.620.670 – staining and labeling MeSH E05.200.500.620.670.130 – chromosome banding MeSH E05.200.500.620.670.325 – in situ hybridization MeSH E05.200.500.620.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.500.620.670.325.350.125 – chromosome painting MeSH E05.200.500.620.670.325.680 – primed in situ labeling MeSH E05.200.500.620.670.520 – negative staining MeSH E05.200.500.620.670.620 – periodic acid-schiff reaction MeSH E05.200.500.620.670.660 – prussian blue reaction MeSH E05.200.500.620.670.770 – shadowing (histology) MeSH E05.200.500.620.670.780 – silver staining MeSH E05.200.500.620.720 – tissue embedding MeSH E05.200.500.620.720.610 – paraffin embedding MeSH E05.200.500.620.720.640 – plastic embedding MeSH E05.200.500.620.760 – tissue preservation MeSH E05.200.500.620.760.160 – cryopreservation MeSH E05.200.500.620.760.160.260 – freeze drying MeSH E05.200.500.620.760.160.260.270 – freeze substitution MeSH E05.200.500.620.760.720 – tissue fixation MeSH E05.200.500.695 – karyometry MeSH E05.200.500.800 – patch-clamp techniques
=== Spectrum of susceptibility === Vancomycin is a last-resort medication for the treatment of sepsis and lower respiratory tract, skin, and bone infections caused by Gram-positive bacteria. The minimum inhibitory concentration susceptibility data for a few medically significant bacteria are:
== History == MMPs were described initially by Jerome Gross and Charles Lapiere in 1962, who observed enzymatic activity (collagen triple helix degradation) during tadpole tail metamorphosis (by placing a tadpole tail in a collagen matrix plate). Therefore, the enzyme was named interstitial collagenase (MMP-1). Later, it was purified from human skin (1968), and was recognized to be synthesized as a zymogen. The "cysteine switch" was described in 1990.
Sources: en.wikipedia.org
=== EC 7.3 Catalysing the translocation of inorganic anions === This subclass contains translocases that transfer inorganic cations anions. Subclasses are based on the reaction processes that provide the driving force for the translocation. At present only one subclass is represented: EC 7.3.2 Translocation of inorganic anions linked to the hydrolysis of a nucleoside triphosphate.
Duterte has been linked by human rights groups such as Amnesty International and Human Rights Watch to extrajudicial killings of over 1,400 alleged criminals and street children by vigilante death squads. In the April 2009 UN General Assembly of the Human Rights Council, the UN report (Eleventh Session Agenda item 3, par 21) said, "The Mayor of Davao City has done nothing to prevent these killings, and his public comments suggest that he is, in fact, supportive." Duterte emphasized that the concept of human rights for criminals is Western and should not apply to the Philippines; he further challenged human rights officials to file a case against him if they could provide evidence of his links with vigilante groups.
He later offered to repay the sum, but Political Quarterly, which had paid the prize money, instead invited him to make a donation to English PEN, of which George Orwell had been a member. Hari arranged with English PEN to make a donation equal to the value of the prize, to be paid in installments when he returned to work at The Independent, but he did not return to work there.
=== Property nationalized === In 1974, the Peruvian government nationalized properties in Peru owned by the company. Harold Logan, Grace's executive vice president, stated the company would join in governmental-level talks over compensation of expropriated American concerns. The loss of Grace's properties in Peru began in 1969 when 25,000 acres of sugarcane plantations were taken over in agrarian reform. The sugar lands were at Paramonga, 110 miles north of Lima, and at Cartavio, near Trujillo, 200 miles farther up the coast. Grace retained small mining operations producing copper, tin, and silver, in southern Peru, about 100 miles north of Juliaca. Jose E. Flores, head of W. R. Grace S.A. Peru, closed the mining operations for Grace in Latin America when the government of Peru nationalized the remaining interests.
Most Spanish Americans saw no reason to recognize a rump government that was under the threat of being captured by the French at any moment, and began to work for the creation of local juntas to preserve the region's independence from the French. Junta movements were successful in New Granada (Colombia), Venezuela, Chile and Río de la Plata (Argentina). Less successful, though serious movements, also occurred in Central America. Ultimately, Central America, along with most of New Spain, Quito (Ecuador), Peru, Upper Peru (Bolivia), the Caribbean and the Philippine Islands remained under control of royalists for the next decade and participated in the Cortes of Cádiz efforts to establish a liberal government for the Spanish monarchy.
Sources: en.wikipedia.org
==== Microbiological use ==== Acetylcysteine can be used in Petroff's method of liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium. It also displays significant antiviral activity against influenza A viruses. Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Staphylococcus epidermidis, and Klebsiella pneumoniae.
== In medicine == In medicine, immunophilins act as receptors for immunosuppressive drugs such as sirolimus (rapamycin), cyclosporin (such as CsA) and tacrolimus (FK506), which inhibit the prolyl isomerase activity of the immunophilins. The drug-immunophilin complexes (CsA-CyP and FK506-FKBP) bind to calcineurin, which inhibits the phosphatase activity of calcineurin and engenders the immunosuppressive effects. CsA and FK506 thus affect the calcium-dependent step of T cell response which prevents release of interleukin-2. Immunophilins also form protein complex with ryanodine and inositol triphosphate (IP3) which impacts the release of calcium. FK506 binds with high affinity to other smaller proteins, such as FKBP-12. FKBP-12 and cyclophilins both share common peptide-prolyl isomerase activity. While the majority of the Peptide bonds within proteins exist in trans (planar) conformation because of the partial double-bond nature of the peptide bond, a small fraction occurs in cis. Unlike regular peptide bonds, the X-Pro peptide bond does not adopt the intended trans conformation spontaneously, thus, cis-trans isomerization can be the rate-limiting (slowest) step in the process of protein folding. Immunophilins, with their prolyl isomerase activity, thus function as protein-folding chaperones.
The planters of the Dutch colony of Suriname relied heavily on African slaves to cultivate, harvest and process the commodity crops of coffee, cocoa, sugar cane and cotton plantations. The Netherlands abolished slavery in Suriname in 1863. Many slaves escaped the plantations. With the help of the native South Americans living in the adjoining rain forests, these runaway slaves established a new and unique culture in the interior that was highly successful in its own right. They were known collectively in English as Maroons, in French as Nèg'Marrons (literally meaning "brown negroes", that is "pale-skinned negroes"), and in Dutch as Marrons. The Maroons gradually developed several independent tribes through a process of ethnogenesis, as they were made up of slaves from different African ethnicities. These tribes include the Saramaka, Paramaka, Ndyuka or Aukan, Kwinti, Aluku or Boni, and Matawai. The Maroons often raided plantations to recruit new members from the slaves and capture women, as well as to acquire weapons, food and supplies. They sometimes killed planters and their families in the raids. The colonists also mounted armed campaigns against the Maroons, who generally escaped through the rain forest, which they knew much better than did the colonists. To end hostilities, in the 18th century the European colonial authorities signed several peace treaties with different tribes. They granted the Maroons sovereign status and trade rights in their inland territories, giving them autonomy.
Specimens, which can vary from a full human body to a small piece of an animal organ, are known as 'plastinates'. Once plastinated, the specimens and bodies are further manipulated and positioned prior to curing (hardening) of the polymer chains.
== Medical uses == Labetalol is effective in the management of hypertensive emergencies, postoperative hypertension, pheochromocytoma-associated hypertension, and rebound hypertension from beta blocker withdrawal. It has a particular indication in the treatment of pregnancy-induced hypertension which is commonly associated with pre-eclampsia. It is also used as an alternative in the treatment of severe hypertension. Labetalol is useful in the treatment of acute cardiovascular toxicity (e.g. in overdose) caused by sympathomimetics like amphetamine, methamphetamine, cocaine, ephedrine, and pseudoephedrine. Other beta blockers are also used. However, the controversial yet possible phenomenon of "unopposed α-stimulation" with administration of selective beta blockers to block non-selective sympathomimetics potentially makes dual alpha-1 and beta blockers like labetalol and carvedilol more favorable for such purposes. The rate of unopposed α-stimulation with selective beta blockers has been reported to be 0.4%, whereas no cases of unopposed α-stimulation have been reported with dual alpha and beta blockers like labetalol.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.